ELOC and breast carcinoma: We show that in breast cancer cells Rab40b does bind to the CRL5 E3 ligase complex containing Cullin5, Elongin B, Elongin C, and Rbx2 and that mutations to the Rab40b–SOCS box are sufficient to disrupt this interaction.